


Compliance Today – February 2024



Sariah Hopkins
(sariah@atlanticbehavioral.com,
[linkedin.com/in/sariah/](https://www.linkedin.com/in/sariah/)) is Chief
Executive Officer at Atlantic Health
Strategies in West Palm Beach, FL.



Leah Kendall
(leah@atlanticbehavioral.com,
[linkedin.com/in/leah-kendall/](https://www.linkedin.com/in/leah-kendall/)) is
Chief Compliance Officer at Atlantic
Health Strategies in West Palm
Beach, FL.

Navigating compliance in harm reduction

by Sariah Hopkins, CHC, and Leah Kendall

The opioid epidemic—a profound public health crisis—underscores the complexities and challenges of addressing substance misuse in contemporary society. As healthcare professionals, policymakers, and communities grapple with the enormity of the crisis, the principles of harm reduction emerge as both a beacon of hope and a subject of debate. At the heart of this discussion is medication-assisted treatment (MAT), a strategy that blends the strengths of pharmacology with behavioral therapies. Yet, its implementation is riddled with legal, ethical, and regulatory challenges, painting a complex landscape for compliance professionals.

Unraveling the philosophy of harm reduction

To understand harm reduction, one must first journey back to its origins. Emerging in the 1980s amidst the burgeoning HIV epidemic, harm reduction was a pragmatic response to the rapid spread of the virus among intravenous drug users. It began with simple measures: providing clean needles to prevent HIV transmission. However, as the years passed, harm reduction expanded its ambit to include a broader range of strategies, all united by a common goal: reducing the negative consequences of drug use.

Harm reduction, as a concept, breaks away from traditional dichotomies of drug policy. Instead of oscillating between punitive measures and total permissiveness, it carves out a middle path emphasizing safety, dignity, and health. By recognizing the multidimensional reasons individuals use drugs, from self-medication to societal pressures, harm reduction seeks to minimize the dangers associated with drug use, advocating for safe practices and supportive environments.

One of the most widely accepted methods of harm reduction is MAT. Rooted in the philosophy that seeks to reduce the adverse health, social, and economic consequences of drug use without necessarily mandating complete abstinence, MAT integrates behavioral therapy and medications to treat substance use disorders (SUDs). By alleviating withdrawal symptoms and reducing cravings, MAT can play a pivotal role in enabling individuals to regain control of their lives while concurrently decreasing the risks associated with illicit drug use, such as overdoses and transmission of infectious diseases.

Expanding the horizon of MAT

MAT is not a single type of treatment but a spectrum of treatments tailored to an individual's needs. It represents a paradigm shift from purely behavioral or punitive approaches to a more integrated methodology.

Methadone: Once hailed as a revolutionary treatment for heroin addiction, methadone’s journey has been marked by successes and challenges. Its ability to replace the euphoric highs of opioids with a steady, controlled state made it a preferred choice for many. Yet, controversies around its potential for misuse and its stringent administration controls have sparked debates.

Buprenorphine: A game-changer in MAT, buprenorphine’s partial opioid agonist properties allow it to relieve withdrawal symptoms without producing the high or dangerous side effects of other opioids. Its versatility extends to its administration; it can be prescribed in various healthcare settings, bridging gaps in treatment accessibility.

Naltrexone: Distinct from methadone and buprenorphine, naltrexone operates as an opioid antagonist. Instead of suppressing withdrawal and cravings, it blocks the euphoric effects of opioids and alcohol. This characteristic makes it particularly valuable for individuals seeking to maintain abstinence post-detoxification.

Emerging treatments are also broadening the MAT horizon. Ketamine—traditionally an anesthetic—is witnessing burgeoning interest for its potential in addressing treatment-resistant depression and certain SUDs. Clinical trials and studies indicated that even low doses of ketamine could provide rapid relief from depressive symptoms—often within hours—especially for individuals resistant to traditional antidepressants. Though not fully understood, the mechanism is believed to be tied to ketamine’s influence on glutamate, a neurotransmitter that plays a pivotal role in neural activation. As research unfolds, the scope and applicability of ketamine in MAT remain areas of keen interest. While some clinics and healthcare providers offer ketamine-assisted therapy for mental health conditions, it’s important to note that the regulatory landscape and medical guidelines for its use are still evolving and will add additional legal intricacies and regulatory procedures.

This document is only available to members. Please log in or become a member.

[Become a Member Login](#)